AstraZeneca China - Search News

AstraZeneca shares rise

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Hosted on MSN · 6h

AstraZeneca shares rise as China probe update reassures

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.

The Financial Times · 11h

AstraZeneca sales jump despite troubles in China

Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.

AstraZeneca faces potential fines in China

Evening Standard on MSN · 11h

AstraZeneca faces potential fines in China over import taxes

Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales of cancer drugs helped drive revenues higher. AstraZeneca said authorities in Shenzhen have said the unpaid taxes amount to 0.

The Mirror · 6h

Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes

AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with other staff members by Chinese authorities

This Is Money on MSN · 9h

AstraZeneca faces potential fines in China over unpaid import taxes

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with Chinese authorities.

8hon MSN

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China

The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

10h

AstraZeneca CEO says company has no access to executive Wang, in detention in China

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

5hon MSN

AstraZeneca gains as Q4 results clear China overhang

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...

5h

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

1d

AstraZeneca shareholders say they need clarity on China investigations

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

1don MSN

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

2d

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results